By Steven Herne, CEO of Unlearn

Unlearn started with a bold mission: to advance AI to eliminate trial and error in medicine, beginning with clinical trials. Under the visionary leadership of Unlearn’s founder and Chief Scientist, Charles Fisher, we focused on pushing the boundaries of AI and machine learning to solve some of the hardest problems in healthcare. Over the past seven years, we have built world-class AI technology that generates digital twins—virtual models of patients that forecast their health outcomes—poised to deliver on that ambitious mission.

Now, we’re entering a new phase. The research and development that got us here was crucial, but we’re no longer just an R&D company. We’re a product-based business, and it’s time to bring that technology to market at scale. That’s why I’ve taken on the role of CEO—to lead Unlearn through this next chapter of commercial growth.

Why Pharma Needs to Evolve—Fast

The pharmaceutical industry is at a turning point. We've made incredible advances in science, but how we run clinical trials is still stuck in the past. It’s slow, expensive, and full of inefficiencies that delay life-saving treatments from reaching patients. On top of that, failure rates are disappointingly high. This outdated process is holding back progress at a time when we should be moving faster than ever.

The question isn’t whether pharma will embrace innovation—it’s how quickly companies can adopt new technologies to solve these problems. This is why I’m excited to be leading Unlearn. With a solid foundation of groundbreaking AI research, we’re now focused on delivering products that will fundamentally change how trials are designed and conducted, removing the bottlenecks that impede progress.

The Unlearn Platform: The AI-Powered Solution Pharma Needs

At the heart of our approach is the Unlearn Platform, built on years of pioneering AI research and development. The Platform delivers digital twins of clinical trial participants to our customers, empowering sponsors to make faster, data-driven decisions. This isn’t just theory—it’s happening today. We’ve partnered with major pharmaceutical companies, demonstrating that we can cut trial timelines, reduce the size of control groups, and increase the likelihood of success. We’re delivering real results in some of the most complex therapeutic areas, and we’re just getting started.

The impact of our platform goes beyond just speeding up trials. By predicting how patients will respond to treatment, we unlock new insights into why certain drugs work and for whom. This opens up huge possibilities for precision medicine, where treatments can be tailored to specific patient subgroups. That’s the future of healthcare, and we’re helping build it.

Right now, we’re focusing on areas like neurology and psychiatry, where the need for innovation is particularly urgent. But our vision is much bigger: we want the Unlearn Platform to be a fundamental part in every clinical trial, across all therapeutic areas, worldwide.

The Path Forward: Speed, Intelligence, and Scale

The future of drug development is one where trials are faster, smarter, and more adaptable. Pharma companies need to run trials that can keep up with the pace of scientific discovery, and we’re giving them the tools to do it. We’re not here to make incremental improvements—we’re here to fundamentally rethink what’s possible in clinical research.

At Unlearn, AI isn’t just a tool—it’s the key to unlocking the full potential of medical innovation. We’re committed to scaling our platform to bring these benefits to as many companies, researchers, and patients as possible.

The industry is ready for change. We’re here to make it happen.

‍